Needham Issues a Hold Rating on BioCryst (BCRX)

By Ryan Adsit

In a report released today, Serge Belanger from Needham assigned a Hold rating to BioCryst (BCRXResearch Report). The company’s shares closed last Wednesday at $10.19.

According to, Belanger is a 4-star analyst with an average return of 9.1% and a 49.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.

BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $14.29.

See today’s analyst top recommended stocks >>

Based on BioCryst’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.02 million and GAAP net loss of $60.49 million. In comparison, last year the company earned revenue of $39.73 million and had a GAAP net loss of $2.62 million.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.